The biotechnology sector has experienced a significant boom in venture capital funding over the past three years. With over 3,100 biotech start-up investments in 2021 alone, the industry is evolving rapidly. This surge in funding signals the potential for groundbreaking advancements in drug discovery, targeting, and delivery. In this article, we will explore the key biotech investment themes that are reshaping the industry and paving the way for a brighter future.
Investment in Next-Generation Biotech Platforms
Venture capital companies have invested over $52 billion globally in therapeutic-based biotech companies from 2019 to 2021. Notably, two-thirds of this funding went to start-ups with platform technologies. These emerging technologies aim to tailor treatments to individual patients and deliver them with greater accuracy. Here are six platform technologies that have generated significant excitement among investors:
- Cell therapy 2.0: These therapies address diseased tissues or cells with greater precision, including solid tumors.
- Next-generation gene therapies: These therapies edit and modulate DNA and RNA, offering potential cures for genetic diseases.
- Precision medicine: This approach diagnoses conditions earlier and tailors therapies based on patients’ specific genetic profiles.
- Machine learning-enabled drug discovery: By cutting through vast amounts of data, machine learning expedites the discovery and development of new drugs.
- Strategies for “undruggable” targets: Biotech companies are developing approaches to target hard-to-hit proteins and treat difficult diseases.
- New delivery methods: Innovations in drug delivery allow novel therapies to reach affected tissues with precision and safety.
Six Biotech Platform Technologies with Transformative Potential
Each biotech platform technology that attracts investment has the potential to address crucial challenges and push technical boundaries. Let’s take a closer look at some of these platforms:
Cell Therapy 2.0
Approved cell therapies have already generated billions of dollars in sales, revolutionizing the treatment of hematologic malignancies. However, challenges such as safety and treatment duration persist. To overcome these hurdles, scientists are exploring innovative approaches:
- Innate immune cells: Some start-ups are shifting their focus from T cells to innate immune cells, such as natural killer cells, because they have better penetration capabilities. These companies have secured significant funding and are expanding their research.
- Precision control of cell therapy: Synthetic biology and complex logic are harnessed to control cell therapies precisely, reducing safety concerns. Companies employing this technology have completed successful funding rounds.
- In vivo cell therapy: Researchers are exploring ways for patients to produce CAR T cells within their bodies, eliminating the need for extraction and manipulation in manufacturing facilities.
Next-Generation Gene Therapies
Gene therapies have shown immense promise for the treatment of genetic disorders. However, challenges remain, including limited specificity and safety concerns. Biotech companies are focusing on next-generation strategies to overcome these obstacles:
- RNA-based modalities and editing: Start-ups are developing new RNA-editing tools and exploring ways to modulate protein expression with innovative RNA classes.
- Novel nucleases: Enzyme discovery and AI-enabled platforms have led to the development of novel Cas nucleases, promising improved efficiency and targeting specificity.
- Non-nuclease editing and modulation: Conventional CRISPR-Cas9 gene editing has limitations, but new technologies like base and prime editors offer precise editing options.
Precision Medicine
Precision medicine utilizes diagnostics and analytics to maximize the effectiveness of therapeutics by considering individual variability. While breakthroughs have already been achieved, there are still challenges to address:
- Early disease detection: Advanced multiomic tools can scan millions of circulating biomarkers to detect early signs of disease, going beyond existing diagnostics.
- Biomarker discovery: Integrated multiomic data sets enable the identification of novel biomarkers and genetic targets for patient subpopulations.
- Precision population health: Biotech companies leverage complex genomic data to guide disease prevention and treatment decisions, providing interpretative services for clinicians.
Machine Learning-Enabled Drug Discovery
Machine learning has the potential to revolutionize drug discovery by predicting molecular behavior and accelerating the design and optimization of drugs. However, challenges such as limited data sets and algorithms’ interpretability need to be addressed. Here are three areas where innovation is occurring:
- Target identification: ML is increasingly used for phenotypic screening and understanding disease mechanisms. Genetic-profiling platforms identify new genetic variants and potential targets.
- Rational drug design: Start-ups aim to apply predictive models across multiple targets, enhancing design capabilities through robotic platforms and generative algorithms.
- Lead validation and optimization: Algorithms scan libraries of molecules to select candidates for clinical development, addressing the lack of high-quality training data.
Strategies for Validated but Undruggable Targets
Conventional drug modalities often cannot target proteins that are considered undruggable. However, the biopharma industry is making progress in delivering drugs to these challenging targets. Promising approaches include:
- New small-molecule binding sites: Advanced techniques and computational methods are used to identify binding sites on proteins that can be targeted by small molecules.
- Protein degradation: This modality promotes selective protein degradation, overcoming the need to identify binding sites.
- Novel disease targets: Biotech companies study disease biology to identify new targets in hard-to-treat illnesses, utilizing advanced analytics and genetic variations.
New Delivery Methods
Advancements in drug delivery are crucial for targeted therapies. Lipid nanoparticles, like those used in mRNA-based COVID-19 vaccines, have shown promise. However, challenges such as limited tissue accessibility and triggering immune responses remain. Here are three bioengineering approaches being explored:
- Improved capsids: ML-driven improvements to adenoassociated virus vectors and the discovery of new vector capsids enhance drug delivery capabilities.
- Biological vehicles: The body’s natural signaling system, such as exosomes, is engineered to deliver therapies to various tissues.
- Enhanced nanoparticles: Optimized nanoparticle compositions expand the range of tissues that therapies can reach.
Achieving Long-Term Benefit from Biotech Platform Technologies
While venture capital investment is driving innovation in the biotech industry, there are several challenges that need to be addressed to realize the full potential of these technologies:
- Differentiating incremental innovations: Start-ups need to differentiate themselves from competitors and demonstrate the unique value of their products. Advocacy for a regulatory framework that can assess new technologies without head-to-head comparisons is crucial.
- Addressing more intractable diseases: Biotech companies should focus on underaddressed diseases and design unique products that target less common conditions. This allows them to go beyond conditions with a well-understood mechanism.
- Demonstrating value for cost-constrained healthcare systems: To develop products that can benefit larger patient populations at lower costs, manufacturing processes need to evolve, and R&D must become more efficient.
With substantial investment in innovative therapies and the potential to overcome existing challenges, the biotech industry is on the verge of transforming how diseases are treated. Cheaper, safer, and more efficacious therapies are within reach, allowing the industry to touch the lives of millions of patients worldwide.
